Literature DB >> 18583930

Novel anticancer compounds induce apoptosis in melanoma cells.

Uppoor G Bhat1, Patricia A Zipfel, Douglas S Tyler, Andrei L Gartel.   

Abstract

We previously described the identification of a nucleoside analog transcriptional inhibitor ARC (4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-Pyrrolo[2,3-d]-pyrimidine-5-carboxamide) and FoxM1 inhibitor, thiazole antibiotic Siomycin A that were able to induce apoptosis in cancer cell lines of different origin. Here, we report the characterization of these drugs on a panel of melanoma cell lines. We found that in contrast to the common anti-melanoma drug dacarbazine (DTIC), ARC and thiazole antibiotics, Siomycin A and thiostrepton, efficiently inhibited growth and induced cell death in melanoma cell lines in low concentrations. Overexpression of the antiapoptotic protein Mcl-1 protected melanoma cells from apoptosis induced by these compounds. Furthermore, we found that ARC and Siomycin A synergistically induce apoptosis in DM833 melanoma cell line suggesting that they may antagonize different anti-apoptotic pathways in melanoma cells. In general, these drugs may represent important candidates for anti-cancer drug development against melanoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583930     DOI: 10.4161/cc.7.12.6032

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  42 in total

1.  Thiostrepton, proteasome inhibitors and FOXM1.

Authors:  Andrei L Gartel
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

2.  Effects of FOXM1 inhibition and ionizing radiation on melanoma cells.

Authors:  Vivienne S Lee; Lucinda S McRobb; Vaughan Moutrie; Estavam D Santos; Timothy L Siu
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

3.  The transcription factor FOXM1 is a cellular target of the natural product thiostrepton.

Authors:  Nagaratna S Hegde; Deborah A Sanders; Raphaël Rodriguez; Shankar Balasubramanian
Journal:  Nat Chem       Date:  2011-08-21       Impact factor: 24.427

4.  Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension.

Authors:  Jingbo Dai; Qiyuan Zhou; Haiyang Tang; Tianji Chen; Jing Li; Pradip Raychaudhuri; Jason X-J Yuan; Guofei Zhou
Journal:  Cell Signal       Date:  2018-08-06       Impact factor: 4.315

5.  Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.

Authors:  Barbara Fontanals-Cirera; Dan Hasson; Chiara Vardabasso; Raffaella Di Micco; Praveen Agrawal; Asif Chowdhury; Madeleine Gantz; Ana de Pablos-Aragoneses; Ari Morgenstern; Pamela Wu; Dan Filipescu; David Valle-Garcia; Farbod Darvishian; Jae-Seok Roe; Michael A Davies; Christopher R Vakoc; Eva Hernando; Emily Bernstein
Journal:  Mol Cell       Date:  2017-11-16       Impact factor: 17.970

6.  Proteasome inhibitory activity of thiazole antibiotics.

Authors:  Bulbul Pandit; Uppoor G Bhat; Andrei L Gartel
Journal:  Cancer Biol Ther       Date:  2011-01-01       Impact factor: 4.742

7.  Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway.

Authors:  Ichiro Nakano; Kaushal Joshi; Koppany Visnyei; Bin Hu; Momoko Watanabe; Diana Lam; Eric Wexler; Kuniyasu Saigusa; Yuko Nakamura; Dan R Laks; Paul S Mischel; Mariano Viapiano; Harley I Kornblum
Journal:  Neuro Oncol       Date:  2011-05-09       Impact factor: 12.300

8.  Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts.

Authors:  Ming Wang; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2011-09-08       Impact factor: 6.261

9.  New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.

Authors:  Bulbul Pandit; Andrei L Gartel
Journal:  Prostate       Date:  2010-06-01       Impact factor: 4.104

10.  FoxM1 is a general target for proteasome inhibitors.

Authors:  Uppoor G Bhat; Marianna Halasi; Andrei L Gartel
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.